State investments in psychiatric innovation: investigating unmeasured state factors

We apply three separate panel data estimation methods to examine the diffusion of technologies at the state-level. These methods include the Hausman–Taylor random effects model, the fixed effects vector decomposition, and generalized estimating equations. We discuss the assumptions required of each and assess the stability of our policy results across the three models for a longitudinal study of the diffusion of newer psychotropic technologies. We find a reasonable level of consistency among marginal effects for time varying independent variables between our three estimation methods but some discrepancy in the estimated measure of precision in our empirical application. We find a number of policy conclusions are quite stable across estimation methods and may be of interest to state-level mental health policy decision makers.

[1]  D. Owens,et al.  Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. , 2008, Annals of internal medicine.

[2]  Paul G Shekelle,et al.  Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. , 2011, JAMA.

[3]  J. Newhouse,et al.  Some economics of mental health 'carve-outs'. , 1996, Archives of general psychiatry.

[4]  Robert P. Rebelein,et al.  Differences in the cost of antidepressants across state Medicaid programs. , 2008, The journal of mental health policy and economics.

[5]  R. J. Vogel.  Health care finance: by Robert J. Buchanan. Heath, Lexington, MA, 1981. 174 pp. $23.95 , 1983 .

[6]  W. Greene,et al.  Fixed Effects Vector Decomposition: A Magical Solution to the Problem of Time-Invariant Variables in Fixed Effects Models? , 2011, Political Analysis.

[7]  M. Domino.  Does managed care affect the diffusion of psychotropic medications? , 2012, Health economics.

[8]  J. Lieberman,et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. , 2006, The American journal of psychiatry.

[9]  Vera E. Troeger,et al.  Fixed-Effects Vector Decomposition: Properties, Reliability, and Instruments , 2011, Political Analysis.

[10]  M. Valenstein,et al.  Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. , 2006, Psychiatric services.

[11]  J. Lyons,et al.  Regional variation and clinical indicators of antipsychotic use in residential treatment: A four-state comparison , 2004, The Journal of Behavioral Health Services & Research.

[12]  B. Martin,et al.  Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. , 2011, Health services research.

[13]  M. Swartz,et al.  Who are the new users of antipsychotic medications? , 2008, Psychiatric services.

[14]  Tom S. Clark,et al.  Should I Use Fixed or Random Effects? , 2014, Political Science Research and Methods.

[15]  Alisa B. Busch,et al.  The effect of a managed behavioral health carve-out on quality of care for medicaid patients diagnosed as having schizophrenia. , 2004, Archives of general psychiatry.

[16]  Tania M Wilkins,et al.  Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder , 2011, Annals of Internal Medicine.

[17]  E. Berndt,et al.  Introduction to "Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches" , 2007 .

[18]  R. Rosenheck,et al.  From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. , 2002, The American journal of psychiatry.

[19]  J. Banthin,et al.  Trends in Prescription Drug Expenditures by Medicaid Enrollees , 2006, Medical care.

[20]  Nathaniel L. Beck.  Of Fixed-Effects and Time-Invariant Variables , 2011, Political Analysis.

[21]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[22]  R. Stafford,et al.  Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.

[23]  K. Huang,et al.  Are Recessions Good for Your Health? When Ruhm Meets GHH , 2014 .

[24]  R. Frank,et al.  Changes in mental health financing since 1971: implications for policymakers and patients. , 2006, Health affairs.

[25]  D. Staiger,et al.  Technology Adoption from Hybrid Corn to Beta Blockers , 2005 .

[26]  E. Norton,et al.  Cost-Shifting in Managed Care , 1999 .

[27]  K. Grazier,et al.  Mental Health Carve-Outs: Effects and Implications , 1999, Medical care research and review : MCRR.

[28]  L. Baker,et al.  Association of managed care market share and health expenditures for fee-for-service Medicare patients. , 1999, JAMA.

[29]  J. Guo,et al.  Utilization, price, and spending trends for antidepressants in the US Medicaid Program. , 2008, Research in social & administrative pharmacy : RSAP.

[30]  E. Berndt,et al.  Economic Incentives and Contracts: The Use of Psychotropic Medications , 2008 .

[31]  E. Norton,et al.  Cost Shifting in a Mental Health Carve-Out for the AFDC Population , 1997, Health care financing review.

[32]  L. Baker,et al.  The effect of HMOs on fee-for-service health care expenditures: evidence from Medicare. , 1997, Journal of health economics.

[33]  M. Duggan.  Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. , 2005, Journal of health economics.

[34]  D. Salkever,et al.  Price elasticity and pharmaceutical selection: the influence of managed care. , 2003, Health economics.

[35]  H. Huskamp.  How a managed behavioral health care carve-out plan affected spending for episodes of treatment. , 1998, Psychiatric services.

[36]  M. Palta,et al.  Causes, Problems and Benefits of Different Between and Within Effects in the Analysis of Clustered Data , 2002, Health Services and Outcomes Research Methodology.

[37]  S. Soumerai,et al.  Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. , 2008, Psychiatric services.

[38]  Z. Griliches.  Hybrid Corn and the Economics of Innovation. , 1960, Science.

[39]  Thomas Plümper,et al.  Efficient Estimation of Time-Invariant and Rarely Changing Variables in Finite Sample Panel Analyses with Unit Fixed Effects , 2007, Political Analysis.

[40]  H. Huskamp.  Episodes of mental health and substance abuse treatment under a managed behavioral health care carve-out. , 1999, Inquiry : a journal of medical care organization, provision and financing.

[41]  Michael B. Ward,et al.  FEVD: Just IV or Just Mistaken? , 2011, Political Analysis.

[42]  William D. Berry,et al.  Measuring Citizen and Government Ideology in the American States , 1998 .